Arkadios Wealth Advisors Makes New Investment in Kenvue Inc. (NYSE:KVUE)

Key Points

• Arkadios Wealth Advisors recently acquired a new position in Kenvue Inc., purchasing 18,448 shares valued at approximately $442,000.
• Analysts have lowered their price targets for Kenvue, with the average target now at $24.79, while the stock currently trades at around $21.65.
• Kenvue has increased its quarterly dividend to $0.2075 per share, reflecting a dividend yield of 3.8%, despite a high payout ratio of 149.09%.

Arkadios Wealth Advisors acquired a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 18,448 shares of the company's stock, valued at approximately $442,000.

Several other institutional investors and hedge funds have also made changes to their positions in KVUE. First National Trust Co raised its stake in shares of Kenvue by 3.3% in the first quarter. First National Trust Co now owns 58,985 shares of the company's stock worth $1,414,000 after purchasing an additional 1,858 shares during the last quarter. Tredje AP fonden raised its position in Kenvue by 120.9% during the first quarter. Tredje AP fonden now owns 584,703 shares of the company's stock valued at $14,021,000 after acquiring an additional 320,000 shares in the last quarter. Vestcor Inc raised its position in Kenvue by 13.6% during the first quarter. Vestcor Inc now owns 37,754 shares of the company's stock valued at $905,000 after acquiring an additional 4,529 shares in the last quarter. Banque Cantonale Vaudoise purchased a new position in Kenvue during the first quarter valued at approximately $2,069,000. Finally, GSA Capital Partners LLP raised its position in Kenvue by 309.0% during the first quarter. GSA Capital Partners LLP now owns 41,885 shares of the company's stock valued at $1,004,000 after acquiring an additional 31,644 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 0.9%

NYSE KVUE traded down $0.19 on Wednesday, reaching $21.45. 30,341,775 shares of the company were exchanged, compared to its average volume of 17,485,301. The business's fifty day moving average price is $21.75 and its 200 day moving average price is $22.40. The stock has a market capitalization of $41.15 billion, a P/E ratio of 39.00, a price-to-earnings-growth ratio of 3.72 and a beta of 0.83. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a fifty-two week low of $19.75 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The company had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same quarter in the prior year, the company posted $0.28 earnings per share. Kenvue's revenue for the quarter was down 3.9% compared to the same quarter last year. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend is Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is currently 150.91%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of analyst reports. UBS Group decreased their price objective on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research report on Thursday, July 17th. Redburn Atlantic initiated coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Bank of America cut their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Barclays decreased their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. cut their price target on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, July 25th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $24.79.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.